Publications by authors named "Anna-Mari Hokkanen"
Article Synopsis
- The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
- Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
- The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.
Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria.
Objectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.
Methods: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.
Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Rheumatology (Oxford)
July 2024
Article Synopsis
- The study aimed to explore sex differences in patient-reported outcomes (PROMs) among patients with axial spondyloarthritis (axSpA) starting their first tumor necrosis factor inhibitor (TNFi).
- Data from 15 registries were analyzed, focusing on changes in BASDAI and BASFI scores over 24 months using linear mixed models.
- Results indicated that women reported significantly worse outcomes than men, with the sex differences in scores nearly doubling after 6 months, and baseline characteristics such as HLA-B27 positivity and disease duration helped explain some but not all of the differences.
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Lancet Reg Health Eur
October 2023
Article Synopsis
- This report compares treatment recommendations for two types of arthritis, PsA and axSpA, in different European countries.
- Rheumatologists from 15 countries answered a survey, showing that only a few countries fully followed the latest recommendations.
- The findings suggest that some countries might need to change their treatment guidelines to match the newer international ones better.
Objective: The aim was to investigate the effect of TNF inhibitor (TNFi) initiation on working ability and health-care resource utilization among axial SpA patients in a real-life setting.
Methods: Patients with a clinical diagnosis of non-radiographic (nr-axSpA) or radiographic axial SpA initiating their first TNFi were identified from the National Register for Antirheumatic and Biologic Treatment in Finland. Sickness absences, including sick leave and disability pension, in- and outpatient days and rehabilitation rates, 1 year before and after initiating the medication were retrieved from national registries.
Article Synopsis
- The study examines the safety of secukinumab compared to TNF inhibitors (TNFi) in treating axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), particularly focusing on the risk of infections.
- Data was gathered from Nordic rheumatology registers between 2015 and 2018, analyzing hospitalized infections within the first year of treatment for both medications.
- The findings indicate that the first-year risk of hospitalization due to infections is significantly higher for secukinumab (3.5%) compared to adalimumab (1.7%), but this increased risk may be influenced by underlying patient conditions (confounding by indication).
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Arthritis Care Res (Hoboken)
May 2022
Article Synopsis
- The study aimed to compare the effectiveness of secukinumab and tumor necrosis factor inhibitors (TNFi), particularly adalimumab, in treating patients with spondyloarthritis (SpA).
- Data were collected from Nordic rheumatology registries on patients starting treatment between 2015 and 2018, focusing on comorbidities and treatment outcomes like retention rates and response to therapy after 6 months.
- Results showed that secukinumab had similar 1-year retention rates as adalimumab for first and second-line treatments but significantly lower retention in third-line treatments, along with poorer 6-month response rates across all treatment lines.
Objectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.
Methods: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.